Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAC1 | P63000 | 4/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 1.00 |
| ▸ | ACHE | P22303 | 8/20 | 0.98 |
| ▸ | MAOB | P27338 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.89 |
| ▸ | MAPT | P10636 | 5/20 | 0.89 |
| ▸ | RAD52 | P43351 | 5/20 | 0.89 |
| ▸ | KDM1A | O60341 | 4/20 | 0.89 |
| ▸ | LMNA | P02545 | 4/20 | 0.89 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.89 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.89 |
| ▸ | POLB | P06746 | 1/20 | 0.89 |
| ▸ | GAA | P10253 | 1/20 | 0.89 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.89 |
| ▸ | EP300 | Q09472 | 6/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.80 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.80 |
| ▸ | APP | P05067 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3320114 | 0.99 | RAC1 (1.00) | RAC1CYP1B1ACHEMAOBCYP3A4 | |
| Columbamine SCHEMBL29395690 | 0.94 | CYP3A4 (1.00) | RAC1CYP1B1ACHEMAOBCYP3A4 | |
| Jatrorrhizine SCHEMBL29368316 | 0.94 | CYP3A4 (1.00) | RAC1CYP1B1ACHEMAOBCYP3A4 | |
| Jatrorrhizine SCHEMBL29381269 | 0.94 | CYP3A4 (1.00) | RAC1CYP1B1ACHEMAOBCYP3A4 | |
| Columbamine SCHEMBL422073 | 0.94 | CYP3A4 (1.00) | RAC1CYP1B1ACHEMAOBCYP3A4 | |
| Jatrorrhizine SCHEMBL564128 | 0.94 | CYP3A4 (1.00) | RAC1CYP1B1ACHEMAOBCYP3A4 | |
| Jatrorrhizine SCHEMBL1427435 | 0.93 | CYP3A4 (0.98) | RAC1CYP1B1ACHEMAOBCYP3A4 | |
| Jatrorrhizine SCHEMBL31238510 | 0.93 | CYP3A4 (0.98) | RAC1CYP1B1ACHEMAOBCYP3A4 | |
| Jatrorrhizine SCHEMBL21809027 | 0.93 | CYP3A4 (0.98) | RAC1CYP1B1ACHEMAOBCYP3A4 | |
| Columbamine SCHEMBL3324164 | 0.93 | CYP3A4 (0.98) | RAC1CYP1B1ACHEMAOBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4326227-A1 | STABILIZED FORMULATIONS | ModernaTX, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20220370616-A1 | STABILIZED FORMULATIONS | ARES CAPITAL CORPORATION, AS AGENT | 2022-11-24 | — | — | US | disclosed |
| WO-2022226277-A1 | STABILIZED FORMULATIONS | MODERNATX, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| CN-115192573-A | Application of demethyleneberberine hydrochloride in preparation of medicine for treating pulmonary fibrosis | 中国药科大学 | 2022-10-18 | — | — | CN | disclosed |
| CN-112294808-B | Application of hydrochloric acid demethyleneberberine acetate in preparation of medicine for preventing or treating drug-induced liver injury | 南京线靶生物医药科技有限公司 | 2022-07-05 | — | — | CN | disclosed |
| WO-2021162750-A1 | BERBERINE COMPOUNDS, BERBERINE COMPOSITIONS, AND METHODS FOR ADMINISTRATION THEREOF | DIGNITY HEALTH (US) | 2021-08-19 | — | — | WO | disclosed |
| US-20200230118-A1 | USE OF BERBERINE OR ACTIVE METABOLITE THEREOF IN PREPARATION OF DRUG FOR PREVENTING AND/OR TREATING PHENYLKETONURIA | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2020-07-23 | — | — | US | disclosed |
| US-9610281-B2 | Use and preparation method of berberine compounds | DALIAN INSTITUTE OF CHEMICAL PHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2017-04-04 | — | — | US | disclosed |
| US-20150164870-A1 | USE AND PREPARATION METHOD OF BERBERINE COMPOUNDS | UNIVERSITY OF CALIFORNIA, IRVINE | 2015-06-18 | — | — | US | disclosed |
| US-8815900-B2 | Compounds and compositions for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2014-08-26 | — | — | US | disclosed |
| US-20100120810-A1 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | EXONHIT THERAPEUTICS SA (FR) | 2010-05-13 | — | — | US | disclosed |
| US-20100120810-A1 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | EXONHIT THERAPEUTICS SA (FR) | 2010-05-13 | — | — | US | disclosed |
| EP-2070926-A1 | 13,13a-DIHYDROBERBERINE DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITION AND USE | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2009-06-17 | — | — | EP | disclosed |
| US-20090048246-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LIMITED (KY) | 2009-02-19 | — | — | US | disclosed |
| WO-2009007457-A2 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | EXONHIT THERAPEUTICS SA (FR) | 2009-01-15 | — | — | WO | disclosed |
| EP-2014651-A1 | Compounds and methods for modulating Rho GTPases | Exonhit Therapeutics SA (FR) | 2009-01-14 | — | — | EP | disclosed |
| US-20080081781-A1 | Administering berberine related or derivative compound; hyperlipidemia, obesity, diabetes, insulin resistance, hyperglycemia, hypertension, elevated cholesterol | INSTITUTE OF MEDICINAL BIOTECHNOLOGY (CN) | 2008-04-03 | — | — | US | disclosed |
| US-20050013788-A1 | Sorptive composite materials | PREENTEC AG (CH) | 2005-01-20 | — | — | US | disclosed |
| EP-1441849-A1 | SORPTIVE COMPOSITE MATERIALS | Tenaxis Gmbh (CH) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003037505-A1 | SORPTIVE COMPOSITE MATERIALS | PREENTEC AG (CH) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120810-A1 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | RAC1, RAC2, RAC3 | RAC1 1/4885CYP1B1 3916/4885ACHE 4129/4885 |
| US-20080081781-A1 | Administering berberine related or derivative compound; hyperlipidemia, obesity, diabetes, insulin resistance, hyperglycemia, hypertension, elevated cholesterol | INSR, HMGCR, GPR119 | RAC1 3542/4885CYP1B1 495/4885ACHE 652/4885 |
| US-20220370616-A1 | STABILIZED FORMULATIONS | RNMT, NSUN2, POLN | RAC1 3414/4885CYP1B1 4118/4885ACHE 4790/4885 |
| US-20050013788-A1 | Sorptive composite materials | MATR3, CD14, SORBS1 | RAC1 2947/4885CYP1B1 4585/4885ACHE 3007/4885 |
| US-20090048246-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | LIPC, BCHE, LIPE | RAC1 1813/4885CYP1B1 1911/4885ACHE 276/4885 |
| US-20200230118-A1 | USE OF BERBERINE OR ACTIVE METABOLITE THEREOF IN PREPARATION OF DRUG FOR PREVENTING AND/OR TREATING PHENYLKETONURIA | PAH, BCKDK, BHMT | RAC1 3936/4885CYP1B1 83/4885ACHE 2327/4885 |
| US-20150164870-A1 | USE AND PREPARATION METHOD OF BERBERINE COMPOUNDS | OPRK1, OPRD1, OPRL1 | RAC1 3401/4885CYP1B1 671/4885ACHE 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.